Home > Healthcare > Pharmaceuticals > Finished Drug Form > Dyspepsia Drugs Market

Dyspepsia Drugs Market Share

Report ID: GMI7670
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Dyspepsia Drugs Market Share

The dyspepsia drugs industry is expected to witness dynamic shifts, driven by innovation, changing consumer preferences, and the pursuit of more effective and patient-friendly treatment options. Established players such as AstraZeneca plc, Takeda Pharmaceutical Company Limited, Pfizer, Inc. are prominent contributors, leveraging their diversified portfolio to address dyspeptic symptoms. These companies also invest in research and development to discover novel compounds and formulations for dyspepsia treatment, aiming for improved efficacy and reduced side effects.

Dyspepsia Drugs Market Companies

Prominent players operating in the dyspepsia drugs industry are as mentioned below:

Takeda Pharmaceutical Company Limited
AstraZeneca plc
Salix Pharmaceuticals, Inc.
Abbott Laboratories
Pfizer Inc.
Sanofi SA
Procter & Gamble
Haleon plc
ANI Pharmaceuticals, Inc.
Dr Reddy’s Laboratories Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Dyspepsia drugs industry size accounted for USD 9.7 billion in 2023 and is set to register 4.5% CAGR to reach USD 14.3 billion by 2032 driven by increasing prevalence of dyspepsia, growing aging population, and rising preference for over the counter (OTC) drugs/medications.

The functional dyspepsia segment accounted for USD 6.9 billion in 2023 and poised to grow at a swift pace through 2032 owing to its high prevalence.

North America dyspepsia drugs industry will reach USD 6.1 billion by 2032 with CAGR of 4.4% over the next decade driven by high prevalence of dyspepsia, alongside a higher incidence of gastroesophageal reflux disease (GERD).

Takeda Pharmaceutical Company Limited, AstraZeneca plc, Salix Pharmaceuticals, Inc., Abbott Laboratories are some of the major industry contenders.